Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
28 Março 2022 - 8:30AM
Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera
Biopharma”), a leading biopharmaceutical company creating
next-generation immune therapies that focus on immune restoration
and homeostasis, announced today that the Company will host a
conference call and live audio webcast on Thursday, March 31, 2022,
at 5:30 p.m. ET, to discuss its corporate and financial results for
the fourth quarter and full year ended December 31, 2021.
Conference Call & Webcast
Details
Date |
Thursday, March 31, 2022 |
Time |
5:30 p.m. ET |
Live Audio Webcast |
https://edge.media-server.com/mmc/p/yffrdzzp |
Telephone Access: U.S. and Canada |
800-937-6813 |
Telephone Access: International |
213-660-0853 |
Access Code for All Callers |
5398016 |
A replay of the webcast will be archived in the
“Investors” section of the Company’s website at
https://www.staterabiopharma.com/investors/ for 90 days beginning
at approximately 8:30 p.m. ET on Thursday, March 31, 2022.
About Statera Biopharma,
Inc.Statera Biopharma, Inc. (formerly Cytocom, Inc.) is a
clinical-stage biopharmaceutical company developing novel
immunotherapies targeting autoimmune, neutropenia/anemia, emerging
viruses and cancers based on a proprietary platform designed to
rebalance the body’s immune system and restore homeostasis. Statera
Biopharma has a large platform of toll-like receptor (TLR) agonists
with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod
and GP532. TLRs are a class of protein that plays a key role in the
innate immune system. Statera Biopharma is developing therapies
designed to directly elicit within patients a robust and durable
response of antigen-specific killer T-cells and antibodies, thereby
activating essential immune defenses against autoimmune,
inflammatory, infectious diseases, and cancers. Statera Biopharma
has clinical programs for Crohn’s disease (STAT-201), hematology
(Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205)
in addition to potential expansion into fibromyalgia and multiple
sclerosis. To learn more about Statera Biopharma, please visit
www.staterabiopharma.com.
Forward Looking Statements:
This press release contains forward-looking statements that involve
risks and uncertainties. All statements other than statements of
current or historical fact contained in this press release,
including statements regarding the Company’s expected clinical
development timeline for the Company’s product candidates, future
financial position, business strategy, new products, budgets,
liquidity, cash flows, projected costs, regulatory approvals, the
impact of any laws or regulations applicable to the Company, and
plans and objectives of management for future operations, are
forward-looking statements. The words “anticipate,” “believe,”
“continue,” “should,” “estimate,” “expect,” “intend,” “may,”
“plan,” “project,” “will,” and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have
based these forward-looking statements on the current expectations
about future events held by management. While we believe these
expectations are reasonable, such forward-looking statements are
inherently subject to risks and uncertainties, many of which are
beyond the Company’s control. The Company’s actual future results
may differ materially from those discussed here for various
reasons. The Company discusses many of these risks under the
heading “Risk Factors” in the proxy statement/prospectus filed with
the SEC on June 10, 2021, as updated by the Company’s other filings
with the SEC.
Given these uncertainties, you should not place
undue reliance on these forward-looking statements. The
forward-looking statements included in this press release are made
only as of the date hereof. We do not undertake any obligation to
update any such statements or to publicly announce the results of
any revisions to any of such statements to reflect future events or
developments.
Contacts:Statera
BiopharmaNichol OchsnerExecutive V.P. Investor Relations
and Corporate Communications(732)
754-2545nichol.ochsner@staterabiopharma.com
FINN PartnersGlenn Silver
(Media) (973) 818-8198glenn.silver@finnpartners.com
FINN PartnersDavid Carey
(IR)(212) 867-1768David.carey@finnpartners.com
Statera BioPharma (NASDAQ:STAB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Statera BioPharma (NASDAQ:STAB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024